NCT01685138 - LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer | Biotech Hunter

Enrollment

124

Participants

Timeline

Start Date

December 20, 2012

Primary Completion Date

January 22, 2018

Study Completion Date

January 22, 2018

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG

LDK378

LDK378/Ceritinib was supplied as 150 mg hard gelatin capsules and administered orally

Trial Locations (51)

407

Novartis Investigative Site, Taichung

1142

Novartis Investigative Site, Auckland

2065

Novartis Investigative Site, St Leonards

3000

Novartis Investigative Site, Leuven

3199

Novartis Investigative Site, Franston

3600

Novartis Investigative Site, Genk

10002

Novartis Investigative Site, Taipei

10043

Novartis Investigative Site, Orbassano

10330

Novartis Investigative Site, Bangkok

10400

Novartis Investigative Site, Bangkok

10700

Novartis Investigative Site, Bangkok

11217

Novartis Investigative Site, Taipei

16132

Novartis Investigative Site, Genova

20089

Novartis Investigative Site, Rozzano

20141

Novartis Investigative Site, Milan

28046

Novartis Investigative Site, Madrid

28050

Novartis Investigative Site, Madrid

29010

Novartis Investigative Site, Málaga

37203

Sarah Cannon Research Institute Drug Ship - 4, Nashville

44805

Novartis Investigative Site, Saint-Herblain

63110

Washington University School of Medicine Washington University (16), St Louis

70403

Novartis Investigative Site, Tainan City

75390

U of TX Southwestern Medical Center - SimmonsCompCancerCtr Clinical Research Office, Dallas

83100

Novartis Investigative Site, Avellino

90110

Novartis Investigative Site, Songkhla

115478

Novartis Investigative Site, Moscow

169610

Novartis Investigative Site, Singapore

197022

Novartis Investigative Site, Saint Petersburg

454087

Novartis Investigative Site, Chelyabinsk

02114

Massachusetts General Hospital Mass Gen 5, Boston

M5G 2M9

Novartis Investigative Site, Toronto

S7N 4H4

Novartis Investigative Site, Saskatoon

Unknown

Novartis Investigative Site, Hong Kong

464 8681

Novartis Investigative Site, Nagoya

277 8577

Novartis Investigative Site, Kashiwa

811-1395

Novartis Investigative Site, Fukuoka

673-8558

Novartis Investigative Site, Akashi

589 8511

Novartis Investigative Site, Sayama

411 8777

Novartis Investigative Site, Sunto Gun

104-0045

Novartis Investigative Site, Chuo-ku

135 8550

Novartis Investigative Site, Koto Ku

NO-0424

Novartis Investigative Site, Oslo

03080

Novartis Investigative Site, Seoul

05505

Novartis Investigative Site, Seoul

06351

Novartis Investigative Site, Seoul

03722

Novartis Investigative Site, Seoul

08916

Novartis Investigative Site, Badalona

08035

Novartis Investigative Site, Barcelona

SE 171 76

Novartis Investigative Site, Stockholm

CO3 3NB

Novartis Investigative Site, Colchester

SE1 9RT

Novartis Investigative Site, London